Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA).

Mestron A, Webb SM, Astorga R, Benito P, Catala M, Gaztambide S, Gomez JM, Halperin I, Lucas-Morante T, Moreno B, Obiols G, de Pablos P, Paramo C, Pico A, Torres E, Varela C, Vazquez JA, Zamora J, Albareda M, Gilabert M.

Eur J Endocrinol. 2004 Oct;151(4):439-46.

2.

Acromegaly.

Scacchi M, Cavagnini F.

Pituitary. 2006;9(4):297-303. Review.

PMID:
17077948
3.

[Epidemiology of acromegaly in Spain].

Sesmilo G.

Endocrinol Nutr. 2013 Oct;60(8):470-4. doi: 10.1016/j.endonu.2012.09.010. Epub 2012 Dec 13. Review. Spanish.

PMID:
23246411
4.

Discordant growth hormone and IGF-1 levels post pituitary surgery in patients with acromegaly naïve to medical therapy and radiation: what to follow, GH or IGF-1 values?

Brzana JA, Yedinak CG, Delashaw JB, Gultelkin HS, Cook D, Fleseriu M.

Pituitary. 2012 Dec;15(4):562-70. doi: 10.1007/s11102-011-0369-1.

PMID:
22183781
5.

The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma.

Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JR, Shalet SM.

Clin Endocrinol (Oxf). 1998 Nov;49(5):653-7. Review.

PMID:
10197082
6.

Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.

Serri O, Beauregard C, Hardy J.

J Clin Endocrinol Metab. 2004 Feb;89(2):658-61.

PMID:
14764777
7.

Effect of transsphenoidal surgery on sleep apnoea in acromegaly.

Sze L, Schmid C, Bloch KE, Bernays R, Brändle M.

Eur J Endocrinol. 2007 Mar;156(3):321-9.

8.

AcroBel--the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects.

Bex M, Abs R, T'Sjoen G, Mockel J, Velkeniers B, Muermans K, Maiter D.

Eur J Endocrinol. 2007 Oct;157(4):399-409.

9.

Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA).

Sesmilo G, Gaztambide S, Venegas E, Picó A, Del Pozo C, Blanco C, Torres E, Álvarez-Escolà C, Fajardo C, García R, Cámara R, Bernabeu I, Soto A, Villabona C, Serraclara A, Halperin I, Alcázar V, Palomera E, Webb SM; REA investigators..

Pituitary. 2013 Mar;16(1):115-21. doi: 10.1007/s11102-012-0384-x.

PMID:
22481632
10.

Effect of different therapeutic modalities on spontaneous GH secretion in acromegalic patients.

Resmini E, Barreca A, Ferone D, Giusti M, Sidoti M, Minuto F.

Clin Endocrinol (Oxf). 2005 Sep;63(3):294-7.

PMID:
16117816
11.

Gender and age influence the relationship between serum GH and IGF-I in patients with acromegaly.

Parkinson C, Renehan AG, Ryder WD, O'Dwyer ST, Shalet SM, Trainer PJ.

Clin Endocrinol (Oxf). 2002 Jul;57(1):59-64.

PMID:
12100070
12.

Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.

Resmini E, Minuto F, Colao A, Ferone D.

Acta Diabetol. 2009 Jun;46(2):85-95. doi: 10.1007/s00592-009-0112-9. Epub 2009 Mar 26. Review.

PMID:
19322513
13.

Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.

Plöckinger U, Quabbe HJ.

Acta Neurochir (Wien). 2005 May;147(5):485-93; discussion 493. Epub 2005 Apr 4.

PMID:
15806331
14.
15.

Acromegaly: an epidemiological study.

Etxabe J, Gaztambide S, Latorre P, Vazquez JA.

J Endocrinol Invest. 1993 Mar;16(3):181-7.

PMID:
8514973
16.

Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.

Sherlock M, Fernandez-Rodriguez E, Alonso AA, Reulen RC, Ayuk J, Clayton RN, Holder G, Sheppard MC, Bates A, Stewart PM.

J Clin Endocrinol Metab. 2009 Apr;94(4):1255-63. doi: 10.1210/jc.2008-1420. Epub 2009 Jan 21.

PMID:
19158203
17.

The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.

Minniti G, Jaffrain-Rea ML, Osti M, Esposito V, Santoro A, Solda F, Gargiulo P, Tamburrano G, Enrici RM.

Clin Endocrinol (Oxf). 2005 Feb;62(2):210-6.

PMID:
15670198
18.

Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women.

Caron P, Broussaud S, Bertherat J, Borson-Chazot F, Brue T, Cortet-Rudelli C, Chanson P.

J Clin Endocrinol Metab. 2010 Oct;95(10):4680-7. doi: 10.1210/jc.2009-2331. Epub 2010 Jul 21.

PMID:
20660047
19.

Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly.

Selvarajah D, Webster J, Ross R, Newell-Price J.

Eur J Endocrinol. 2005 Apr;152(4):569-74.

20.

Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly.

Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS.

J Clin Endocrinol Metab. 2004 Apr;89(4):1613-7.

PMID:
15070920

Supplemental Content

Support Center